Lonza Group AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lonza Group AG
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.
With ten years of experience at Roche under his belt, ten23 CEO and co-founder talked to Scrip about trends in the Swiss manufacturing landscape, from pandemic-related capacity growth to increased demand for small-batch production and sustainability efforts.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.